Mumbai: The Board of Control for Control for Cricket in India (BCCI) has suspended batsman Prithvi Shaw for doping violation until November 15, 2019.
The 19-year-old Indian batsman had “inadvertently ingested a prohibited substance, which can be commonly found in cough syrups,” the BCCI said in a release.
Shaw registered with Mumbai Cricket Association, had provided a urine sample as part of the BCCI’s anti-doping testing program during the Syed Mushtaq Ali Trophy match on 22nd February 2019 in Indore.
His sample was subsequently tested and found to contain Terbutaline.
Terbutaline, a specified substance, is prohibited both In & Out of Competition in the WADA Prohibited List of Substances.
On 16th July 2019, Shaw was charged with the commission of an Anti-Doping Rule Violation (ADRV) under the BCCI Anti-Doping Rules (ADR) Article 2.1 and provisionally suspended pending determination of the charge.
Shaw responded to the charge by admitting the ADRV but asserting that it was inadvertent, being caused by his ingestion of the over the counter cough syrup he had taken for his cough.
The BCCI is satisfied with Mr. Shaw’s explanation that he had taken Terbutaline inadvertently to treat an Respiratory Tract Infection and not as a performance-enhancing drug.
Having considered all of the evidence and taken expert external advice, the BCCI has accepted Shaw’s explanation of the cause of his ADRV, and on that basis has agreed that a period of ineligibility of eight months should apply, together with disqualification of certain results.